<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-042681</identifier>
<setSpec>0212-7199</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Inductionof tolerance in hypersensitivity to mesalazine (5-ASA)</dc:title>
<dc:description xml:lang="en">Mesalazine is a derivative of 5-aminosalicylic acid (5-ASA), which is useful in the treatment of intestinal inflammatory disease. Sulfasalazine is formed by two parts, sulfapyridine and 5-ASA, the latter being the active part of the molecule. The new preparatives derived from 5-ASA were developed in an attempt to avoid the traditionally associated side effects to sulfapyridine, although they are still observed and new effects appear. We present two cases. The first is a man diagnosed of inflammatory intestinal disease, with background of two previous reactions of urticaria and angioedema after acetyl salicylic acid, who presented urticaria after taking mesalazine. The second one had generalized urticaria after three months of initiating treatment with mesalazine. Given the need for treatment in both cases, a desensitization protocol to mesalazine was made. It was developed in 17 days in our service. Tolerance to that drug to therapeutic doses is reached. When faced with patients with hypersensitivity to different drugs, that are necessary to treat their disease, &#147;desensitization&#148; regimes, that assure good tolerance, can be made</dc:description>
<dc:creator>Vázquez Fuertes, L</dc:creator>
<dc:creator>Martínez-Cócera, C</dc:creator>
<dc:creator>González Gutiérrez, M. L</dc:creator>
<dc:creator>Robledo Echarren, T</dc:creator>
<dc:creator>Domínguez Ortega, J</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La mesalazina es un derivado del ácido 5-aminosalicílico (5-ASA, el cual es útil en el tratamiento de la enfermedad inflamatoria intestinal. La sulfasalazina está formada por dos partes, la sulfapiridina y el 5-ASA, siendo ésta última la parte activa de la molécula. Los nuevos preparados derivados del 5-ASA se desarrollaron tratando de evitar los efectos secundarios tradicionalmente asociados a la sulfapiridina, aunque se siguen observando y aparecen nuevos efectos. Presentamos dos casos, el primero es un varón diagnosticado de enfermedad inflamatoria intestinal, con antecedentes de dos reacciones previas de urticaria y angioedema tras ácido acetilsalicílico, que presenta urticaria tras la toma de mesalazina. El segundo presenta urticaria generalizada tras tres meses de iniciar tratamiento con mesalazina. Dada la necesidad de tratamiento en ambos casos, se realiza el protocolo de desensibilización a mesalazina desarrollado en 17 días en nuestro servicio, con el que se llega a la tolerancia de dicho fármaco hasta dosis terapéuticas. Ante pacientes con hipersensibilidad a distintos fármacos, que sean necesarios para el tratamiento de su patología, pueden realizarse pautas de &#147;desensibilización&#148;, que aseguren una buena tolerancia</dc:description>
<dc:source>An Med Interna;22(12): 586-588, dic. 2005. tab</dc:source>
<dc:identifier>ibc-042681</dc:identifier>
<dc:title xml:lang="es">Inducción de tolerancia en la hipersensibilidad a mesalazina (5-ASA)</dc:title>
<dc:subject>^d331</dc:subject>
<dc:subject>^d33400^s22020</dc:subject>
<dc:subject>^d14983^s22036</dc:subject>
<dc:subject>^d4404^s22067</dc:subject>
<dc:subject>^d27938^s22020</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d29373</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:type>article</dc:type>
<dc:date>200512</dc:date>
</metadata>
</record>
</ibecs-document>
